Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2025
Date Filed: September 4, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a notification of a corporate event rather than a financial report.
Material Changes
The primary material event disclosed in this filing is a Trading Halt, submitted as Exhibit 99.1. No other material changes to financial position or operations are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or detailed risk factors beyond the implication of the trading halt. The document notes that this Form 6-K is being incorporated by reference into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific reason and expected duration of the Trading Halt referenced in Exhibit 99.1.
- Confirm the status of the company's development stage operations given the halt.
- Review the referenced Registration Statements (S-8 and F-3) for broader context on capital structure and securities offerings.